Prentiss Smith & CO Inc Novartis Ag Transaction History

Prentiss Smith & CO Inc

  • $148 Million
  • Q3 2024

A detailed history of Prentiss Smith & CO Inc transactions in Novartis Ag stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 48,357 shares of NVS stock, worth $4.76 Million. This represents 3.77% of its overall portfolio holdings.

Number of Shares
48,357
Previous 48,813 0.93%
Holding current value
$4.76 Million
Previous $5.2 Million 7.04%
% of portfolio
3.77%
Previous 3.63%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024
SELL
$106.13 - $120.89 $48,395 - $55,125
-456 Reduced 0.93%
48,357 $5.56 Million
Q2 2024

Jul 17, 2024
SELL
$92.57 - $107.37 $48,784 - $56,583
-527 Reduced 1.07%
48,813 $5.2 Million
Q1 2024

Apr 30, 2024
SELL
$95.27 - $108.47 $115,848 - $131,899
-1,216 Reduced 2.41%
49,340 $4.77 Million
Q4 2023

Feb 02, 2024
SELL
$92.27 - $101.54 $136,190 - $149,873
-1,476 Reduced 2.84%
50,556 $5.1 Million
Q3 2023

Oct 24, 2023
SELL
$94.73 - $105.13 $43,575 - $48,359
-460 Reduced 0.88%
52,032 $5.3 Million
Q2 2023

Aug 02, 2023
SELL
$92.52 - $104.91 $14,525 - $16,470
-157 Reduced 0.3%
52,492 $5.3 Million
Q1 2023

Apr 28, 2023
SELL
$80.03 - $92.81 $50,338 - $58,377
-629 Reduced 1.18%
52,649 $4.84 Million
Q4 2022

Jan 31, 2023
SELL
$75.55 - $92.52 $50,845 - $62,265
-673 Reduced 1.25%
53,278 $4.83 Million
Q3 2022

Oct 21, 2022
SELL
$74.61 - $87.26 $14,623 - $17,102
-196 Reduced 0.36%
53,951 $4.1 Million
Q2 2022

Aug 12, 2022
SELL
$80.52 - $93.75 $70,777 - $82,406
-879 Reduced 1.6%
54,147 $4.58 Million
Q1 2022

May 09, 2022
SELL
$80.11 - $90.62 $133,383 - $150,882
-1,665 Reduced 2.94%
55,026 $4.83 Million
Q4 2021

Jan 28, 2022
SELL
$79.7 - $88.13 $2,311 - $2,555
-29 Reduced 0.05%
56,691 $4.96 Million
Q3 2021

Oct 19, 2021
SELL
$81.78 - $95.14 $13,493 - $15,698
-165 Reduced 0.29%
56,720 $4.64 Million
Q2 2021

Jul 15, 2021
SELL
$85.24 - $94.15 $93,849 - $103,659
-1,101 Reduced 1.9%
56,885 $5.19 Million
Q1 2021

Jun 21, 2021
SELL
$83.5 - $98.47 $577,736 - $681,313
-6,919 Reduced 10.66%
57,986 $4.96 Million
Q4 2020

Feb 03, 2021
SELL
$78.07 - $94.43 $87,516 - $105,856
-1,121 Reduced 1.7%
64,905 $6.13 Million
Q3 2020

Nov 02, 2020
SELL
$82.14 - $91.0 $166,990 - $185,003
-2,033 Reduced 2.99%
66,026 $5.74 Million
Q2 2020

Jul 13, 2020
BUY
$80.93 - $91.1 $2,589 - $2,915
32 Added 0.05%
68,059 $5.94 Million
Q1 2020

Apr 29, 2020
SELL
$70.67 - $99.01 $37,737 - $52,871
-534 Reduced 0.78%
68,027 $5.61 Million
Q4 2019

Jan 21, 2020
SELL
$84.35 - $95.37 $87,892 - $99,375
-1,042 Reduced 1.5%
68,561 $6.49 Million
Q3 2019

Nov 06, 2019
SELL
$85.54 - $94.26 $22,582 - $24,884
-264 Reduced 0.38%
69,603 $6.05 Million
Q2 2019

Jul 19, 2019
SELL
$75.4 - $92.8 $1.68 Million - $2.07 Million
-22,327 Reduced 24.22%
69,867 $6.38 Million
Q1 2019

Jul 01, 2019
SELL
$75.32 - $86.15 $2.2 Million - $2.52 Million
-29,225 Reduced 24.07%
92,194 $8.86 Million
Q4 2018

Jan 15, 2019
SELL
$73.66 - $82.02 $35,504 - $39,533
-482 Reduced 0.4%
121,419 $10.4 Million
Q3 2018

Oct 23, 2018
SELL
$66.94 - $77.43 $91,908 - $106,311
-1,373 Reduced 1.11%
121,901 $10.5 Million
Q2 2018

Jul 19, 2018
SELL
$64.91 - $73.36 $242,179 - $273,706
-3,731 Reduced 2.94%
123,274 $9.31 Million
Q1 2018

Apr 20, 2018
BUY
$70.39 - $84.15 $34,279 - $40,981
487 Added 0.38%
127,005 $10.3 Million
Q4 2017

Feb 13, 2018
BUY
$72.33 - $77.64 $17,793 - $19,099
246 Added 0.19%
126,518 $10.6 Million
Q3 2017

May 03, 2018
BUY
$74.14 - $77.27 $4,744 - $4,945
64 Added 0.05%
126,272 $10.8 Million
Q3 2017

Oct 23, 2017
BUY
$74.14 - $77.27 $9.36 Million - $9.75 Million
126,208
126,208 $10.8 Million

Others Institutions Holding NVS

# of Institutions
1,437
Shares Held
131M
Call Options Held
1.12M
Put Options Held
1.83M
View Full List

About NOVARTIS AG

NVS Quotes by TradingView
  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $212B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Prentiss Smith & CO Inc Portfolio

Follow Prentiss Smith & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prentiss Smith & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email